The latest price target for Lexaria Bioscience (NASDAQ:LEXX) was reported by HC Wainwright & Co. on July 18, 2024. The analyst firm set a price target for $10.00 expecting LEXX to rise to within 12 months (a possible 371.61% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Lexaria Bioscience (NASDAQ:LEXX) was provided by HC Wainwright & Co., and Lexaria Bioscience reiterated their buy rating.

There is no last upgrade for Lexaria Bioscience

There is no last downgrade for Lexaria Bioscience.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lexaria Bioscience, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lexaria Bioscience was filed on July 18, 2024 so you should expect the next rating to be made available sometime around July 18, 2025.

While ratings are subjective and will change, the latest Lexaria Bioscience (LEXX) rating was a reiterated with a price target of $10.00 to $10.00. The current price Lexaria Bioscience (LEXX) is trading at is $2.12, which is out of the analyst’s predicted range.